LUNG INFECTION in ICU (LUNG-I3)

Last updated: February 10, 2025
Sponsor: BioMérieux
Overall Status: Active - Recruiting

Phase

N/A

Condition

Pneumonia

Treatment

N/A

Clinical Study ID

NCT06073834
LUNG-I3
  • Ages > 18
  • All Genders

Study Summary

objective of LUNG-I3 study is to assess the quantitative and functional differences in cells between blood and bronchoalveolar lavage (BAL) fluid after an infection, with a special focus on alveolar macrophages and neutrophils

Eligibility Criteria

Inclusion

Inclusion Criteria:

All the following criteria

  • Age 18 years or greater

  • Severe ICU patients hospitalized for one of the above diseases:

  • Septic shock (requirement of vasopressor to maintain a mean arterial pressureof 65 mm Hg or greater and serum lactate level greater than 2 mmol/L (>18mg/dL) in the absence of hypovolemia) caused either by pneumonia (n=20) oranother source n=20)

  • Severe trauma (level I and II), Injury Severity Score ≥ 25 OR

  • Burn with TBSA over 20%

  • NAD > 0.1 µg/kg/min

  • At least 2 SOFA criteria ≥ 2 points

Exclusion

Exclusion Criteria:

  • Aspiration pneumonia

  • Unable to obtain a valid and written consent from a patient or their legallyauthorized representative in accordance with the local regulatory instances (thisincludes in FR: Person not affiliated to a health insurance scheme, or not abeneficiary of such a scheme. Persons who are the subject of a legal protectionorder. Person with restricted freedom following a legal or administrative decisionand a person admitted without their consent pursuant to Articles L.3212-1 and 3213-1, which are not included in Article L.1121-8 of the French Public HealthCode.)

  • COPD

  • Smoke inhalation in burn patients

  • Participation in an intervention study

  • Pregnant or breastfeeding women

  • Immunocompromised patients, defined as

  • patients with solid tumors with chemotherapy in the last 3 months or aprogressive metastatic disease

  • hematologic malignancies

  • solid organ transplantation

  • HIV infection with or without AIDS

  • treatment with corticosteroids (> 3 months at any dosage or ≥ 1 mg/kgprednisone equivalent per day for > 7 day)

  • treatment with other immunosuppressive drugs.

Study Design

Total Participants: 68
Study Start date:
December 05, 2023
Estimated Completion Date:
June 30, 2027

Connect with a study center

  • Hopital Edouard Herriot

    Lyon, 69003
    France

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.